| 生物活性 |
Caudatin is an orally active, blood-brain barrier-permeable C-21 steroidal compound found in Cynanchum bungei decne that exhibits multiple biological activities: it inhibits cell proliferation, migration, and invasion, induces cell cycle arrest, apoptosis, autophagy, reactive oxygen species (ROS) production, and loss of mitochondrial membrane potential, activates PARP and caspase-3, -7, and -9, upregulates the expression of pro-apoptotic proteins Bad and Bax, downregulates the expression of anti-apoptotic proteins Bcl-2 and Bcl-XL, inhibits the phosphorylation of VEGF and FAK, upregulates the protein expression of p21, p27, and DR5, and activates p38 MAPK, JNK, and the PPARα/TFEB-mediated autophagy-lysosomal signaling pathway, making it useful for research on cancer, inflammation, and neurological diseases such as glioma and Alzheimer's disease. |
体外研究 (In Vitro) |
Caudatin (25-100 μM; 24-72 h) 可以时间和剂量依赖的方式强效抑制人胶质瘤 U251 和 U87 细胞的活性,其中 U251 细胞的敏感性更高 (72 h 时 IC50 = 52.1 μM)。 Caudatin (25-100 μM; 72 h) 可在人胶质瘤 U251 细胞中诱导剂量依赖性凋亡,当以 100 μM Caudatin 处理 72 h 后,有 71.4%的细胞发生凋亡。 Caudatin (12.5-100 μM; 72 h) 可在 72 h 内诱导人胶质瘤 U251 细胞中呈剂量依赖性的 PARP 切割,以及 caspase-3、caspase-7 和 caspase-9 的活化。 Caudatin (25-100 μM; 5-30 min) 可在人胶质瘤 U251 细胞中诱导线粒体膜电位呈时间依赖性丧失。 Caudatin (25-100 μM; 1-72 h) 可破坏人胶质瘤 U251 细胞中 Bcl-2 家族蛋白的平衡,在 72 h 内以剂量依赖方式上调促凋亡蛋白 Bad 和 Bax,同时下调抗凋亡蛋白 Bcl-2 和 Bcl-XL。 Caudatin (25-100 μM; 2-72 h) 可通过诱导呈剂量依赖性的 ROS 和超氧化物积累、降低线粒体质量及 GSH 含量,扰乱人胶质瘤 U251 细胞内的氧化还原稳态。 Caudatin (6-200 μM; 48 h) 可呈剂量依赖性抑制 HUVEC 的增殖,在处理 48 h 后,50、100 和 200 μM 浓度分别将细胞活力降至 71.5%、53.6%和 38.1%。 Caudatin (100 μM; 48 h) 处理 48 h 后可抑制 HUVEC 的迁移。 Caudatin (100 μM; 24 h) 处理 24 h 后可抑制 HUVEC 的侵袭。 Caudatin (100 μM; 24 h) 处理 24 h 后可抑制 HUVEC 的毛细血管样管形成。 Caudatin (50-200 μM; 12-48 h) 可以剂量依赖和时间依赖的方式抑制人脐静脉内皮细胞 (HUVECs) 中 FAK 的磷酸化。 Caudatin (50-200 μM; 48 h) 可以剂量依赖的方式抑制 HUVEC 中 VEGF 和磷酸化 VEGFR2 的表达,且不改变总 VEGFR2 或 AKT 的水平。 Caudatin (5-100 μg/mL; 24 h) 可呈浓度依赖性抑制人 MDA-MB-231 和 MCF-7 乳腺癌细胞的活力。 Caudatin (10-50 μg/mL; 24 h) 可诱导人 MDA-MB-231 和 MCF-7 乳腺癌细胞发生 G1 期细胞周期阻滞。 Caudatin (5-50 μg/mL; 24 h) 可调控关键细胞周期调控因子的表达,包括在人 MDA-MB-231 和 MCF-7 乳腺癌细胞中上调 p21、p27 及 p53,同时下调 p-Cdc2、Cdk4 和 cyclinB1。 Caudatin (5-50 μg/mL; 24 h) 可诱导人 MDA-MB-231 和 MCF-7 乳腺癌细胞发生细胞凋亡,caspase-8、caspase-9 和 PARP 的剂量依赖性剪切可证明这一点。 Caudatin (5-50 μg/mL; 24 h) 可在人 MDA-MB-231 和 MCF-7 乳腺癌细胞中以剂量依赖方式上调 DR5 蛋白表达,且不影响 DR4 的表达。 Caudatin (5-50 μg/mL; 24 h) 可激活人 MDA-MB-231 和 MCF-7 乳腺癌细胞中的内质网应激反应,PERK、BIP、ATF4 和 CHOP 蛋白水平呈剂量依赖性上调可证明这一点。 Caudatin (5-50 μg/mL; 24 h) 可在人 MDA-MB-231 和 MCF-7 乳腺癌细胞中以剂量依赖的方式激活 p38 MAPK 和 JNK 信号通路,且不影响 ERK1/2 的磷酸化。 Caudatin (10-50 μg/mL; 24 h) 可诱导人 MDA-MB-231 和 MCF-7 乳腺癌细胞发生细胞凋亡。 Caudatin 可与人类 PPARα 配体结合域强结合。 Caudatin (25 μM; 24 h) 可逆转 Aβ1-42 诱导的小鼠海马神经元 HT-22 细胞毒性。 Caudatin (6.25-25 μM; 24 h) 呈剂量依赖性诱导小鼠神经细胞发生自噬并促进自噬流。 Caudatin (25 μM; 24 h) 可诱导小鼠小胶质细胞中 PPARα 的核转位,该效应可被 PPARα 抑制剂 GW6471 (MS-V40693) 阻断。 Caudatin (25 μM) 以 PPARα 依赖的方式降低过表达 AD 相关突变的小鼠小胶质细胞中的磷酸化 Tau 蛋白和 APP 代谢物。 Caudatin (6.25-25 μM) 可通过不依赖 MTORC1 的机制,以剂量依赖方式上调小鼠神经元细胞和小胶质细胞中 TFEB 的表达并诱导 TFEB 发生核转位。
Cell Viability Assay
| Cell Line: |
human glioma U251, U87 cells |
| Concentration: |
25, 50, 100 μM |
| Incubation Time: |
24 h; 48 h; 72 h |
| Result: |
Significantly decreased U251 and U87 cell viability in a time- and dose-dependent manner. Reduced U251 cell viability to 73.5%, 51.3%, and 28.2% after treatment with 25, 50, 100 μM for 72 h, respectively. Exhibited IC50 values towards U251 cells of 170.3 μM (24 h), 102.2 μM (48 h), and 52.1 μM (72 h). |
Apoptosis Analysis
| Cell Line: |
human glioma U251 cells |
| Concentration: |
25, 50, 100 μM |
| Incubation Time: |
72 h |
| Result: |
Induced significant dose-dependent apoptosis in U251 cells, as measured by the Sub-G1 peak. Resulted in 10.2%, 34.7%, and 71.4% apoptotic cells after treatment with 25, 50, 100 μM, respectively. |
Western Blot Analysis
| Cell Line: |
human glioma U251 cells |
| Concentration: |
12.5, 25, 50, 100 μM |
| Incubation Time: |
72 h |
| Result: |
Dose-dependently induced PARP cleavage (89 KD fragment) and activation of caspase-3, caspase-7, and caspase-9 in U251 cells. Resulted in PARP cleavage levels (normalized to β-actin) of 0.1, 0.5, 0.9, and 1.0 for 12.5, 25, 50, and 100 μM, respectively. Resulted in active caspase-3 levels of 0.4, 0.4, 0.5, and 1.0 for 12.5, 25, 50, and 100 μM, respectively. Resulted in active caspase-7 levels of 0.5, 0.9, and 1.0 for 25, 50, and 100 μM, respectively. Resulted in active caspase-9 levels of 0.5, 0.7, and 1.0 for 25, 50, and 100 μM, respectively. |
Western Blot Analysis
| Cell Line: |
human glioma U251 cells |
| Concentration: |
25, 50, 100 μM (72 h treatment); 50 μM (time-course treatment) |
| Incubation Time: |
72 h; 1, 6, 12, 24, 48, 72 h (time-course) |
| Result: |
Dose-dependently upregulated pro-apoptotic Bad and Bax expression, and downregulated anti-apoptotic Bcl-2 and Bcl-XL expression in U251 cells after 72 h treatment. Decreased Bcl-2 expression (normalized to β-actin) to 0.9, 0.9, 0.8, 0.1, 0.1, and 0.1 at 1, 6, 12, 24, 48, and 72 h, respectively, with 50 μM treatment. Increased Bad expression to 0.6, 0.7, 0.8, and 1.0 at 12, 24, 48, and 72 h, respectively, with 50 μM treatment. |
Apoptosis Analysis
| Cell Line: |
human glioma U251 cells |
| Concentration: |
50 μM (with 20 μM caspase inhibitor pretreatment) |
| Incubation Time: |
72 h |
| Result: |
Reduced 50 μM caudatin-induced apoptosis from 32.4% to 7.4% when cells were pretreated with z-VAD-fmk, and increased cell viability in caudatin-treated cells. Suppressed caudatin-induced PARP cleavage when cells were pretreated with z-VAD-fmk or z-LEHD-fmk. Suppressed caudatin-induced activation of caspase-3, caspase-7, and caspase-9 when cells were pretreated with z-VAD-fmk or z-DEVD-fmk. |
Cell Viability Assay
| Cell Line: |
human umbilical vein endothelial cells (HUVECs) |
| Concentration: |
6, 12, 25, 50, 100, 200 μM |
| Incubation Time: |
48 h |
| Result: |
Slightly promoted HUVEC growth at 6 μM. Significantly inhibited HUVEC viability in a dose-dependent manner at 25, 50, 100, 200 μM, reducing viability to 71.5% (50 μM), 53.6% (100 μM), and 38.1% relative to control. |
Western Blot Analysis
| Cell Line: |
human umbilical vein endothelial cells (HUVECs) |
| Concentration: |
50, 100, 200 μM (dose-dependent assay); 100 μM (time-dependent assay) |
| Incubation Time: |
48 h; 12, 24, 48 h (time-dependent assay) |
| Result: |
Reduced p-FAK levels in a dose-dependent manner at 50, 100, 200 μM after 48 h. Reduced p-FAK levels in a time-dependent manner at 100 μM after 12, 24, and 48 h. |
Western Blot Analysis
| Cell Line: |
human umbilical vein endothelial cells (HUVECs) |
| Concentration: |
50, 100, 200 μM |
| Incubation Time: |
48 h |
| Result: |
Reduced VEGF and p-VEGFR2 expression in a dose-dependent manner after 48 h, with no significant changes in total VEGFR2 or total AKT levels. |
Cell Cycle Analysis
| Cell Line: |
human MDA-MB-231 and MCF-7 breast carcinoma cells |
| Concentration: |
10, 50 μg/mL |
| Incubation Time: |
24 h |
| Result: |
Increased the G1-phase population to 64.78±0.98% and decreased the G2/M-phase population to 17.75±0.66% in MDA-MB-231 cells at 10 μg/mL. Increased the G1-phase population to 69.76±1.83% and decreased the G2/M-phase population to 11.10±1.14% in MDA-MB-231 cells at 50 μg/mL. Increased the G1-phase population to 57.14±1.11% and decreased the S-phase population to 34.05±1.26% in MCF-7 cells at 10 μg/mL. Increased the G1-phase population to 73.94±2.01% and decreased the S-phase population to 14.99±1.24% in MCF-7 cells at 50 μg/mL. |
Western Blot Analysis
| Cell Line: |
human MDA-MB-231 and MCF-7 breast carcinoma cells |
| Concentration: |
5-50 μg/mL |
| Incubation Time: |
24 h |
| Result: |
Caused dose-dependent accumulation of p21 and p27 proteins in both cell lines. Upregulated p53 protein in MCF-7 cells but not in MDA-MB-231 cells. Downregulated p-Cdc2, Cdk4, and cyclinB1 proteins in both cell lines. Left Cdc2 protein levels unchanged in both cell lines. Caused dose-dependent cleavage of caspase-8, caspase-9, and PARP, hallmark features of apoptosis, in both cell lines. Caused a dose-dependent increase in DR5 protein levels in both cell lines, with no significant change in DR4 protein levels observed. Caused a dose-dependent increase in protein levels of PERK, BIP, ATF4, and CHOP, markers of ER stress and the unfolded protein response, in both cell lines. Caused a dose-dependent increase in phosphorylation of p38 MAPK and JNK in both cell lines, with no significant change in ERK1/2 phosphorylation observed. |
|
体内研究 (In Vivo) |
Caudatin (25-50 mg/kg;静脉注射;每 2 天 1 次;持续 16 天) 可通过诱导细胞凋亡、抑制细胞增殖及阻断血管生成,显著抑制雄性裸鼠体内 U251 人胶质瘤异种移植物的生长,且对小鼠体重无明显影响。 Caudatin (25-50 mg/kg;静脉注射;隔日一次;连续 16 天) 可剂量依赖性地抑制雄性裸鼠皮下 U251 胶质瘤移植瘤的生长;同时该药物可通过下调 VEGF 表达、CD34 阳性血管密度以及 p-AKT/p-FAK 水平来抑制血管生成。 Caudatin (20-40 mg/kg;口服;每日给药,持续 8 个月) 可改善 3XTg-AD 小鼠的认知功能,减少 Aβ 和病理性 Tau 病理改变,激活 PPARα/TFEB 介导的自噬-溶酶体通路,并减轻其神经炎症。 Caudatin (20 mg/kg;灌胃;单次给药) 可透过健康 ICR 小鼠的血脑屏障,在 15 分钟时脑内浓度达峰值 64.77 ng/g。
| Animal Model: |
Nude mice with U251 human glioma xenograft (male) |
| Dosage: |
25 mg/kg; 50 mg/kg |
| Administration: |
i.v.; every other day; 16 days |
| Result: |
Reduced tumor volume and tumor weight compared to control. Induced tumor cell apoptosis (via caspase-3 activation). Inhibited tumor cell proliferation (via reduced Ki-67 staining). Suppressed tumor angiogenesis (via reduced CD-31 staining). Did not affect mouse body weight. |
| Animal Model: |
Nude mice with U251 human glioma xenograft (male) |
| Dosage: |
25 mg/kg; 50 mg/kg |
| Administration: |
i.v.; every other day; 16 days |
| Result: |
Reduced mean tumor volume and mean tumor weight. Dose-dependently reduced phosphorylated AKT (p-AKT) and phosphorylated FAK (p-FAK) levels in tumor tissue. Dose-dependently decreased immunohistochemical staining of Ki-67, VEGF, and CD34 in tumor tissue. |
| Animal Model: |
3XTg-AD (female, 6 months old, Alzheimer's disease model with K670M/N671L, M146V, P301L mutant gene overexpression); 129/B6/SWJ (female, wildtype littermate) |
| Dosage: |
20 mg/kg; 40 mg/kg |
| Administration: |
p.o.; daily; 8 months |
| Result: |
Reduced escape latency in the Morris water maze (MWM) task, increased time spent in the target quadrant during the MWM probe trial, increased freezing percentage in the contextual fear conditioning test, reduced time spent in the center of the open field chamber, and increased total distance traveled in the open field test compared to vehicle-treated 3XTg-AD mice. Reduced AT8-positive neuron load in hippocampal brain slices; significantly lowered sarkosyl-insoluble levels of pathological Tau markers PHF1, AT8, CP13, MC1, and HT7 in brain homogenates. Reduced the number of 4G8-positive Aβ plaques in hippocampal brain slices; significantly lowered formic acid-soluble Aβ1-42 and Aβ1-40 levels in brain homogenates, and reduced SDS-soluble levels of APP metabolites CTFs and pCTFs. Increased brain homogenate protein levels of PPARα, TFEB, mature CTSD, LAMP1, and LC3B-II, while reducing SQSTM1 levels, compared to vehicle-treated 3XTg-AD mice. Reduced the number of activated microglia and astrocytes in brain slices, and lowered corresponding protein levels in brain homogenates. |
|